1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun, MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. Epub 2009 May 27. [PubMed Abstract]
2. Sepulveda C, Prado R. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Cancer Detect Prev. 2005;29:405-11. Epub 2005 Sep 26. [PubMed Abstract]
3. Chi DS, Abu-Rustum NR, Hoskins WJ. Cancer of the Cervix. In: Rock JA, Jones HW III, eds. Te Linde’s Operative Gynecology, 9th ed. Philadelphia: Lippincott, Williams & Wilkins, 2003.
4. Cancer Detection Guidelines. American Cancer Society. Revised 1-2004.
5. Cervical cytology screening. ACOG Practice Bulletin No. 109. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114:1409-1420.
6. Clinical Practice Guidelines in Oncology, Cervical Screening. National Comprehensive Cancer Network. Version 1. 2009.
7. National Cancer Institute (NCI) Guidelines on Cervical Cancer Screening. US Preventive Services Task Force (USPSTF). 2003.
8. Gershenson DM, Copeland LJ, Hoskins WJ, Podratz KC (editors). Reducing the burden of HPV and HPV related diseases: An update for primary care practitioners. Gynecologic Oncology. 2007;107(2): S31-33. [PubMed Abstract]
9. Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. American College of Obstetricians and Gynecologists. September 2006.
10. Hildeshiem A, Berrington de Gonzalez A. Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst. 2006 Mar 1;98(5):292-3. [PubMed Abstract]
11. D’Souza, G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007 May 10;356(19):1944-56. [PubMed Abstract]
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27. [PubMed Abstract]
13. Garland, SM, Hernandez-Avila, M, Wheeler, CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEJM, 2007;356:1928-1943. [PubMed Abstract]
14. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neopalsia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet. 2007 May 31;369(9,576):1861-8. [PubMed Abstract]
15. Advisory Committee on Immunization Practices (ACIP) HPV recommendations. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm?s_cid=rr5602a1_e. Accessed May 15, 2013.
16. American College of Obstetricians and Gynecologists (ACOG) HPV recommendations - http://www.acog.org/. Accessed May 15, 2013.
17. American Academy of Pediatrics (AAP) HPV recommendations - http://www.cispimmunize.org/. Accessed May 15, 2013.
18. Society of Gynecologic Oncologists (SGO) HPV recommendations - https://www.sgo.org/clinical-practice/guidelines. Accessed May 15, 2013.
19. American Cancer Society (ACS) HPV recommendations - http://www.cancer.org/docroot/CRI/content/CRI_2_6x_FAQ_HPV_Vaccines.asp. Accessed May 15, 2013.